QP Solutions

QP Solutions Get your first license, Maintain existing license, Host regulatory inspection, Commercial and clinical batch release, Carry out compliance audits, QP, GXP

http://regulatorycompliancehelp.co.uk/
Are you looking to launch your pharmaceutical products in the U.K. and E.U. markets? Do you also want to make sure you’re fully licenced and legally compliant with all the current and future laws governing pharmaceutical products? Then a pharmaceutical consultancy expert can help you…
Paul Palmer offers a comprehensive ‘done-for-you service’ to managing direc

tors, quality directors and commercial teams looking to sell their products in the U.K. markets and are dealing with issues such as Batch Release, regulatory compliance, reviewing existing working practices and QP declarations. To find out more and receive a free bonus guide worth £37.00, simply visit www.regulatorycompliancehelp.co.uk.

Only 5% of eligible patients ever enrol in a clinical trial.Let that number sit for a moment.Billions are spent on drug ...
12/06/2026

Only 5% of eligible patients ever enrol in a clinical trial.

Let that number sit for a moment.

Billions are spent on drug development every year.
Thousands of trials are running globally at any given time.
And yet — only 1 in 20 eligible patients ever participates.

The result?

Trials that take years longer than they should.
Drugs that are delayed.
Patients who wait.

And when you look at who does participate — it's often not representative of the population who will eventually use the medicine.

Older patients. Underrepresented communities. People with multiple conditions.
Frequently excluded. Rarely centred.

We have a clinical trial system that is extraordinarily good at generating data — and not always good at generating the right data, from the right people, at the right pace.

The industry knows this.
Decentralised trials, patient advocacy partnerships, digital recruitment — the solutions exist.

So why is 5% still the number?

I'd argue the real barrier isn't technology or funding.
It's that patient recruitment has never been treated as a strategic priority the way efficacy or safety data has.

That needs to change.

What's your experience with clinical trial recruitment — from either side of the process?

𝗤𝘂𝗶𝗰𝗸 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻 𝗯𝗲𝗳𝗼𝗿𝗲 𝘆𝗼𝘂 𝗰𝗹𝗼𝘀𝗲 𝘁𝗵𝗲 𝗹𝗮𝗽𝘁𝗼𝗽 𝘁𝗼𝗻𝗶𝗴𝗵𝘁.If a regulator walked into your site tomorrow morning — unannounced —...
11/06/2026

𝗤𝘂𝗶𝗰𝗸 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻 𝗯𝗲𝗳𝗼𝗿𝗲 𝘆𝗼𝘂 𝗰𝗹𝗼𝘀𝗲 𝘁𝗵𝗲 𝗹𝗮𝗽𝘁𝗼𝗽 𝘁𝗼𝗻𝗶𝗴𝗵𝘁.

If a regulator walked into your site tomorrow morning — unannounced —

𝗪𝗼𝘂𝗹𝗱 𝘆𝗼𝘂𝗿 𝘁𝗲𝗮𝗺 𝗳𝗲𝗲𝗹 𝗿𝗲𝗮𝗱𝘆?

Not performing ready.

Not "we've prepared for this" ready.

Actually ready.

Because there's a difference between an organisation that lives its quality culture every day, and one that activates it when an inspection is coming.

Regulators know the difference, too.

One question: 𝘄𝗵𝗮𝘁'𝘀 𝘁𝗵𝗲 𝗼𝗻𝗲 𝘁𝗵𝗶𝗻𝗴 𝗮𝘁 𝘆𝗼𝘂𝗿 𝘀𝗶𝘁𝗲 𝘁𝗵𝗮𝘁 𝘆𝗼𝘂'𝗱 𝘄𝗮𝗻𝘁 𝟮𝟰 𝗺𝗼𝗿𝗲 𝗵𝗼𝘂𝗿𝘀 𝘁𝗼 𝗳𝗶𝘅?

You don't have to answer publicly. But it's worth asking yourself honestly before you log off.

🎯 AI is coming to pharmaceutical quality. It's already here in parts.And I have a question that I don't think the indust...
11/06/2026

🎯 AI is coming to pharmaceutical quality. It's already here in parts.

And I have a question that I don't think the industry has answered clearly yet:

When an AI system flags an anomaly in a batch record and a QP approves the batch anyway, who bears responsibility?

The QP still signs. The QP still holds the licence.

But if the AI said no and the human said yes, and something goes wrong downstream —

How does a regulator interpret that decision?

I'm not raising this to be alarmist. I'm raising it because I've spoken to QPs who are already navigating this in practice, without clear guidance from their organisations or their regulators.

The technology is moving faster than the accountability frameworks around it.

That gap is where risk lives.

I'd genuinely like to know: if you're working with AI tools in your quality systems right now, how is your organisation handling the question of human oversight?

𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 "𝘁𝗵𝗲 𝗤𝗣 𝗶𝘀 𝘀𝘁𝗶𝗹𝗹 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗶𝗯𝗹𝗲" 𝗮𝗰𝘁𝘂𝗮𝗹𝗹𝘆 𝗹𝗼𝗼𝗸 𝗹𝗶𝗸𝗲 𝗶𝗻 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲 𝘄𝗵𝗲𝗻 𝘁𝗵𝗲 𝘀𝘆𝘀𝘁𝗲𝗺 𝗱𝗼𝗲𝘀 𝗺𝗼𝘀𝘁 𝗼𝗳 𝘁𝗵𝗲 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀?

𝗣𝗵𝗮𝗿𝗺𝗮 𝗶𝘀 𝗯𝗿𝗶𝗹𝗹𝗶𝗮𝗻𝘁 𝗮𝘁 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗶𝗻𝗴 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀.We are not always brilliant at developing people.I've seen talented scientis...
11/06/2026

𝗣𝗵𝗮𝗿𝗺𝗮 𝗶𝘀 𝗯𝗿𝗶𝗹𝗹𝗶𝗮𝗻𝘁 𝗮𝘁 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗶𝗻𝗴 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀.

We are not always brilliant at developing people.

I've seen talented scientists leave the industry not because the work stopped being interesting, but because nobody invested in them beyond their technical role.

No mentorship. No visibility. No honest conversation about where they were headed.

And then we wonder why there's a talent shortage in quality and regulatory.

There isn't a shortage of people who want to work in this industry.

There's a shortage of organisations willing to grow them properly.

If you manage people in pharma, here's a challenge:

When did you last have a genuine career conversation, not a performance review, with someone on your team?

Not ticking a box. A real conversation.

If it's been more than three months, that's worth reflecting on today.

The best retention strategy isn't compensation.

It's making people feel like their growth matters to you.

Tag a manager who does this well; let's recognise the good ones.

In 2021, a single plant in Ireland stopped producing a key antibiotic.Within weeks, hospitals across Europe were rationi...
11/06/2026

In 2021, a single plant in Ireland stopped producing a key antibiotic.

Within weeks, hospitals across Europe were rationing it.

Not because of a quality failure.

Not because of a recall.

Simply because too much of the world's supply ran through one building.

We talk a lot in pharma about quality risk.

We don't talk nearly enough about concentration risk.

Right now, a significant share of the world's active pharmaceutical ingredients comes from a handful of manufacturers in India and China.

That's not a criticism. It's a reality and a vulnerability.

The next major drug shortage won't announce itself.

It will start quietly: a single site shutdown, a shipping delay, a geopolitical shift.

And somewhere, a patient will go without.

The question isn't whether this will happen again.

It's whether the industry will be structurally different when it does.

💭 What's your view, is pharma doing enough to build supply chain resilience, or are we still optimising for cost over continuity?

Something I've been sitting with this week.The average pharmaceutical product takes 10–15 years to reach a patient.Thous...
10/06/2026

Something I've been sitting with this week.

The average pharmaceutical product takes 10–15 years to reach a patient.

Thousands of people touch it along the way — scientists, engineers, regulators, manufacturers, QPs, logistics teams.

And then one person opens the box.

They don't know any of those names.
They don't know about the failed batches, the regulatory queries, the late nights before submission.

They just trust that what's inside is exactly what it says it is.

That trust is the entire point of what we do.

On the days when the system feels slow, or the paperwork feels endless, or the pressure is coming from every direction —

Remember who the system was built for.

It wasn't built for the regulator.
It wasn't built for the audit.

It was built for that person opening the box.

𝗣𝗵𝗮𝗿𝗺𝗮 𝗺𝘆𝘁𝗵𝘀 𝘁𝗵𝗮𝘁 𝗻𝗲𝗲𝗱 𝘁𝗼 𝗱𝗶𝗲 𝗶𝗻 𝟮𝟬𝟮𝟲:❌ "More documentation = more compliance."No. More documentation = more risk of inc...
10/06/2026

𝗣𝗵𝗮𝗿𝗺𝗮 𝗺𝘆𝘁𝗵𝘀 𝘁𝗵𝗮𝘁 𝗻𝗲𝗲𝗱 𝘁𝗼 𝗱𝗶𝗲 𝗶𝗻 𝟮𝟬𝟮𝟲:

❌ "More documentation = more compliance."

No. More documentation = more risk of inconsistency.

Write less. Write better.

❌ "If it passed the audit, it's fine."

Audits are a snapshot.

Passing one doesn't mean your system is healthy.

❌ "The QP just signs things off."

The QP is the last line of defence between manufacturing and the patient.

That's not a rubber stamp. That's a responsibility.

❌ "Regulators don't understand our business."

They understand it better than most people think.

They've seen hundreds of companies like yours.

❌ "We'll fix it before the next inspection."

The patients using your product right now aren't waiting for your next inspection.

Which of these have you heard recently?

Drop it in the comments — I'd like to know what's still circulating out there.

In pharmaceutical development, a test result is only as trustworthy as the method behind it. 🔬That's where Analytical Me...
09/06/2026

In pharmaceutical development, a test result is only as trustworthy as the method behind it. 🔬

That's where Analytical Method Validation (AMV) comes in.

Before any testing method is used to assess the quality of a pharmaceutical product, it must be rigorously validated — proving that it consistently measures what it claims to measure, with accuracy, precision, and reproducibility.

Key parameters evaluated during validation include:

✅ Specificity

✅ Linearity & range

✅ Accuracy & precision

✅ Detection & quantitation limits

✅ Robustness

Skipping or rushing this process isn't just a regulatory risk — it's a patient safety risk.

I've just come across a great resource breaking down the AMV process for pharmaceutical quality testing. If you work in QA, R&D, or regulatory affairs, this is worth your time.

📌 Drop a comment or DM me if you'd like the link.

A quality policy framed and hung on the wall isn't a culture. It's a photo.Culture is what happens when no one is watchi...
08/06/2026

A quality policy framed and hung on the wall isn't a culture. It's a photo.

Culture is what happens when no one is watching. It's the decision a technician makes at 11 PM when the supervisor has gone home. It's how a customer complaint is handled without a script. It's the question an engineer asks before signing off on a product.

Embedding quality policy into culture requires:
🎯 Leaders who model quality behavior consistently
🎯Systems that make doing the right thing the easy thing
🎯Recognition of quality-driven decisions at all levels
🎯Honest conversations about quality failures without blame

You can audit a document. You cannot audit a belief.

The organizations that get quality right don't just have a policy. They have a conviction.

Address

Steyning
BN443RQ

Opening Hours

Monday 8am - 10pm
Tuesday 8am - 10pm
Wednesday 8am - 10pm
Thursday 8am - 10pm
Friday 8am - 10pm

Telephone

+441903366167

Website

Alerts

Be the first to know and let us send you an email when QP Solutions posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to QP Solutions:

Shortcuts

Share

Category